Which causes more immunosuppression, azathioprine or steroids (corticosteroids)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Degree of Immunosuppression: Azathioprine vs Corticosteroids

Systemic corticosteroids at doses ≥20 mg for >2 weeks cause more immunosuppression than azathioprine at standard doses, with corticosteroids conferring an 85% increased risk of infections compared to azathioprine's more modest risk profile. 1

Comparative Immunosuppression Classification

The most recent ECCO guidelines (2021) provide a clear framework for comparing these agents:

Corticosteroids

  • Moderate-severe immunosuppression occurs with systemic steroids at doses ≥20 mg for >2 weeks 1
  • Relative risk for infections is 1.85 at doses ≥20 mg compared to 1.10 for doses <5 mg/day 1
  • Morbidity and mortality attributable to corticosteroid treatment is significantly higher, particularly at 1 mg/kg dosing 1
  • Corticosteroids cause immunosuppression primarily through CD4+ T-lymphocyte sequestration and cytokine transcription inhibition 2

Azathioprine

  • Moderate-severe immunosuppression only at doses >3 mg/kg/day 1
  • Standard doses ≤3 mg/kg/day are classified as low-degree immunosuppression 1
  • Azathioprine monotherapy does not cause marked increases in infection susceptibility 3
  • The immunosuppressive effect is primarily through lymphocyte suppression via purine synthesis inhibition 2

Infection Risk Profile Differences

Specific Infection Patterns

  • Corticosteroids are specifically associated with increased fungal infections (particularly Candida) 1
  • Azathioprine is more associated with viral infections (particularly varicella zoster virus) 1, 3
  • The combination of azathioprine plus steroids presents the greatest infection risk, with odds ratios increasing from 2.9 (single agent) to 14.5 (combination therapy) 1

Clinical Context Matters

When these agents are combined, the infection risk amplifies dramatically rather than simply adding together 1. This is particularly relevant in elderly patients with bullous pemphigoid, where combination therapy shows significantly higher mortality 1, 3.

Dose-Dependent Considerations

A critical pitfall is assuming all doses are equivalent:

  • Low-dose corticosteroids (<5 mg/day) have minimal immunosuppressive effects (RR 1.10) 1
  • High-dose corticosteroids (≥20 mg for >2 weeks) cause substantial immunosuppression (RR 1.85) 1
  • Azathioprine at ≤3 mg/kg/day is considered low immunosuppression, while >3 mg/kg/day reaches moderate-severe levels 1

Practical Clinical Algorithm

For determining which agent causes more immunosuppression:

  1. If comparing high-dose steroids (≥20 mg) to standard azathioprine (≤3 mg/kg/day): Steroids cause significantly more immunosuppression 1

  2. If comparing low-dose steroids (<5 mg) to any dose azathioprine: Azathioprine causes more immunosuppression 1

  3. If comparing high-dose azathioprine (>3 mg/kg/day) to high-dose steroids (≥20 mg): Both cause moderate-severe immunosuppression, but steroids have higher infection risk (RR 1.85) 1

Important Caveats

Duration matters critically for steroids: The threshold of >2 weeks at ≥20 mg is what defines moderate-severe immunosuppression 1. Shorter courses may not reach this level.

Topical steroids are different: Oral budesonide up to 6 mg/day for long-term maintenance did not result in higher infection rates compared to placebo 1, demonstrating that route and systemic absorption matter significantly.

Combination therapy is not additive—it's multiplicative: The infection risk with azathioprine plus steroids is far greater than either agent alone, with the combination presenting the greatest risk among all IBD therapies 1.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Pharmacologic immunosuppression.

Frontiers in bioscience : a journal and virtual library, 2004

Guideline

Infection Risk Associated with Azathioprine Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.